StreetInsider.com News Articles

Form 4 MiNK Therapeutics, Inc. For: Jun 04 Filed by: Ryan Barbara

Fri, 05 Jun 2026 18:04:00 -0400

si-local-file:///var/storage/secattach/20260605/26612463.html

Form 4 MiNK Therapeutics, Inc. For: Jun 04 Filed by: Ryan Barbara

Fri, 05 Jun 2026 18:04:00 -0400

si-local-file:///var/storage/secattach/20260605/26612463.html

MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting

Wed, 03 Jun 2026 16:30:00 -0400

NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET. on June 17, 2026, and will be conducted in a virtual format only. Registration for attendees will start at 9:15 a.m. ET.

To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/INKT2026 and enter the 16-digit control number found in their proxy materials. Guests may also access the meeting in listen-only mode. No control number is

MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting

Wed, 03 Jun 2026 16:30:00 -0400

Form 4 MiNK Therapeutics, Inc. For: Mar 02 Filed by: Corvese Brian

Tue, 02 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260602/26591547.html

Form 4 MiNK Therapeutics, Inc. For: Mar 02 Filed by: Corvese Brian

Tue, 02 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260602/26591547.html

Form 4 MiNK Therapeutics, Inc. For: Mar 02 Filed by: Ryan Barbara

Tue, 02 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260602/26591561.html

Form 4 MiNK Therapeutics, Inc. For: Mar 02 Filed by: Ryan Barbara

Tue, 02 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260602/26591561.html

Form 4 MiNK Therapeutics, Inc. For: Mar 02 Filed by: Holcomb John Bradley

Tue, 02 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260602/26591568.html

Form 4 MiNK Therapeutics, Inc. For: Mar 02 Filed by: Holcomb John Bradley

Tue, 02 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260602/26591568.html

Form 4 MiNK Therapeutics, Inc. For: Mar 02 Filed by: WIINBERG ULF

Tue, 02 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260602/26591522.html

Form 4 MiNK Therapeutics, Inc. For: Mar 02 Filed by: WIINBERG ULF

Tue, 02 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260602/26591522.html

Form 4 MiNK Therapeutics, Inc. For: Mar 02 Filed by: Behner Peter

Tue, 02 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260602/26591541.html

Form 4 MiNK Therapeutics, Inc. For: Mar 02 Filed by: Behner Peter

Tue, 02 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260602/26591541.html

MiNK Therapeutics doses first patient in phase 2 lung injury trial

Thu, 28 May 2026 09:05:03 -0400

MiNK Therapeutics (NASDAQ: INKT) announced that the first patient has been dosed in its randomized Phase 2 clinical trial evaluating agenT-797 for acute lung injury and critical illness.

The patient was dosed at First Lviv Territorial Medical Union in Lviv, Ukraine, following approval from Ukraine's Ministry of Health. The trial, designated C-1300-02, compares agenT-797 plus standard care against placebo plus standard care in patients with acute lung injury meeting Global Acute Respiratory Distress Syndrome criteria.

The study evaluates intensive care unit outcomes including survival, ventilator-free days, ICU recovery, and biological measures related to treatment activity and immune function. The company expects preliminary

MiNK Therapeutics doses first patient in phase 2 lung injury trial

Thu, 28 May 2026 09:05:03 -0400

MiNK Therapeutics (NASDAQ: INKT) announced that the first patient has been dosed in its randomized Phase 2 clinical trial evaluating agenT-797 for acute lung injury and critical illness.

MiNK Therapeutics doses first patient in phase 2 lung injury trial

Thu, 28 May 2026 09:05:03 -0400

MiNK Therapeutics (NASDAQ: INKT) announced that the first patient has been dosed in its randomized Phase 2 clinical trial evaluating agenT-797 for acute lung injury and critical illness.

MiNK Therapeutics doses first patient in phase 2 lung injury trial

Thu, 28 May 2026 09:05:03 -0400

MiNK Therapeutics (NASDAQ: INKT) announced that the first patient has been dosed in its randomized Phase 2 clinical trial evaluating agenT-797 for acute lung injury and critical illness.

MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness